Therapeutics for Memory and Cognition Disorders

Published - Apr 2009| Analyst - Maura Warner| Code - PHM054A
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • The global market for therapeutics for memory and cognitive disorders will increase from $6.7 billion in 2008 to an estimated $7.3 billion by the end of 2009. It should reach almost $36.0 billion in 2014, a compound annual growth rate (CAGR) of 37.5%.
  • Treatments for Alzheimer’s disease have the largest share of the market, worth $3.9 billion in 2008. This is expected to increase to $4.4 billion in 2009 and $22.4 billion in 2014, for a CAGR of 38.8%.
  • Treatments for MCI/AACI have the second largest market share, generating $1.6 billion in 2008 and an estimated $1.7 billion in 2009. This should increase at a CAGR of 33.9% to reach $7.1 billion in 2014.


BCC’s goal in conducting this study is to determine the current status of the therapeutics and treatments for memory and cognition deficits and assess the growth potential of this area over a 5-year period from 2009 to 2014. We were particularly interested in how demographics are impacting the development efforts being undertaken currently and how memory/cognition is evolving into a therapeutic focus in its own right.
Our key objective is to present a comprehensive analysis of the current pipeline, the market and forecast for memory/cognition therapeutics and the key factors that will influence this therapeutic area in the next few years. 
As the mechanisms of the central nervous system become more elucidated, the opportunity for treating memory/cognition deficits and related diseases is coming to the forefront. This study aims to quantify where this market is heading and where the opportunities may lie.
Although there are several modes of treating memory and cognitive deficiency, the scope of this report is on the pharmaceutical segment. We have compiled a study of the market, and current and emerging modes of treatment. We present the market segment economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for 2009 to 2014. We also project usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients and the medical community. It will be of interest also to suppliers of products and services to this market area.
The intended audience for this report is the pharmaceutical and biotechnology industries, as well as the medical industry which treats patients in these areas.
Both primary and secondary research methods were used in preparing this study. BCC presents an analysis, by each disease area, of a number of current patients. Then, based on our surveys, we analyze the potential applications for pharmaceuticals, and forecast markets for 2009 and 2014. 
BCC surveyed approximately fifty companies to obtain data for this study. Included were drug development companies and medical professionals. We also spoke with patients affected by memory and cognition diseases.   In addition, we compiled data from current financial and trade information and government sources.
Maura Lane Warner has 16 years of industry experience, as both a chemical engineer and market and business development executive in the pharmaceutical and biotechnology industries. She has a BS in Chemical Engineering and an MBA in Marketing. Ms. Lane Warner has also authored a report on Microfluidics. 
BCC offers an online information retrieval service. BCC’s home page, located at enables readers to: 
  • Examine BCC’s complete catalog of market research reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Note: Reports are discounted or included with certain Memberships. See Membership Options.

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report